Using mass spectrometry to identify and quantify HCPs enables a more rational development of robust purification processes.
HCP Watchlist & Knockout Targets for Biotherapeutic Development Read More »
The 2018 Vanderlaan et al. publication remains one of the most insightful summaries of biopharma’s experience with host cell proteins (HCPs). It includes a case study on MCP-1—an HCP linked to adverse events—that underscores why accurate detection, monitoring, and clearance during process development are critical to product safety. Essential reading for scientists, process developers, and anyone working
HCP Spotlight: Understanding MCP-1 in Biologics Read More »
A highly efficient method of plasma fractionation that has the potential to address the growing global IG product shortage. Read the Case Study Now:
Developing a New Plasma Fractionation Process for IVIG Read More »
The Role of a COO in Scaling Bioanalytical Excellence In the fast-evolving world of bioanalytical CROs, achieving operational excellence while fostering innovation is critical. Large molecule drug development, GMP stability testing, and custom sample collection devices require precision, agility, and strategic leadership. As COO, my role is to ensure our bioanalytical services operate efficiently while
Operational Excellence in Bioanalytical Services: A COO’s View Read More »
